RxDoctor Payments Data

Julio Menocal, MD

Family Medicine · Frederick, MDNPI 1164492401

Payments from drug & device makers

$4,523in general payments, 2019–2025

Across 317 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$705
  • AbbVie$576
  • AstraZeneca$566
  • Pfizer$332
  • Boehringer Ingelheim$223
  • GSK$201
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,523 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$376,718
Medicare patients
983
Services billed
11,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide205$213,492
EliquisApixaban129$159,696
JardianceEmpagliflozin121$154,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter156$109,895
TrulicityDulaglutide90$90,049
MounjaroTirzepatide70$78,919
JanuviaSitagliptin Phosphate57$72,232
XareltoRivaroxaban40$53,390
FarxigaDapagliflozin Propanediol36$36,526
RybelsusSemaglutide12$24,358
TradjentaLinagliptin18$24,106
Bydureon BciseExenatide Microspheres23$24,051
EntrestoSacubitril/Valsartan17$22,925
Tresiba Flextouch U-200Insulin Degludec24$22,208
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$20,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$705$237,850217 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$223$194,787172 claims
Lilly USA, LLCTrulicity, Mounjaro$197$168,968160 claims
PfizerEliquis$332$159,696129 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$201$126,028193 claims
MerckJanuvia$175$72,23257 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$566$61,56275 claims
Johnson & JohnsonXarelto$44$53,39040 claims
AbbVieRestasis$576$6,98911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$57$3,832353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →